Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Breast Neoplasms 81Carcinoma, Non-Small-Cell Lung 76Neoplasms 71Ovarian Neoplasms 68Neoplasm Metastasis 30Fallopian Tube Neoplasms 30Carcinoma, Ovarian Epithelial 29Lung Neoplasms 26Unspecified Adult Solid Tumor, Protocol Specific 24Triple Negative Breast Neoplasms 20Endometrial Neoplasms 20Esophageal Neoplasms 18Stomach Neoplasms 16Colorectal Neoplasms 14Squamous Cell Carcinoma of Head and Neck 13Head and Neck Neoplasms 13Solid Tumors 12Small Cell Lung Carcinoma 10Melanoma 10Pancreatic Neoplasms 9Uterine Cervical Neoplasms 8Prostatic Neoplasms 8Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma 8Carcinoma, Renal Cell 8Carcinoma 8Brenner Tumor 8Urinary Bladder Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7

Interventions

Bevacizumab 7Paclitaxel 3vesencumab 2atezolizumab 2Carboplatin 21-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one 2peginterferon alfa-2a 1parsatuzumab 1ovcon 35 1onartuzumab 1obinutuzumab 1ipatasertib 1emactuzumab 1Vitamin D 1Trastuzumab 1Rosiglitazone 1Pemetrexed 1Ipilimumab 1Interferon alpha-2 1HhAntag691 1Grape Seed Extract 1GDC-0623 1GDC-0152 1Docetaxel 1Cisplatin 1Capecitabine 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Solid Cancers × Paclitaxel × Clear all
NCT00954642 2017-05-17

A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors

Genentech, Inc.

Phase 1 Completed
24 enrolled

Solid Cancers

NCT01075464 2016-11-02

A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors

Genentech, Inc.

Phase 1 Completed
64 enrolled

Solid Cancers

NCT01301716 2016-11-02

A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors

Genentech, Inc.

Phase 1 Completed
75 enrolled

Solid Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡